Betaine Suppresses Lipid Accumulation in Liver: Inhibition of FoxO6 and PPARγ Interaction

Area of Science:

• Molecular Biology
• Hepatology
• Nutritional Science

Background:

• Betaine, a component of Lycium chinensis, shows potential in fatty liver disease treatment.
• The precise molecular mechanisms behind betaine's protective effects on hepatic steatosis remain unclear.
• Hyperglycemia-induced hepatic lipid accumulation is a key factor in fatty liver disease progression.

Purpose of the Study:

• To elucidate the molecular regulation of betaine on hyperglycemia-induced hepatic lipid accumulation.
• To investigate betaine's effect on the Forkhead box O (FoxO)6/peroxisome proliferator-activated receptor gamma (PPARγ) signaling pathway.
• To determine if betaine ameliorates hepatic steatosis by inhibiting FoxO6/PPARγ signaling.

Main Methods:

• Utilized HepG2 cells and liver tissue from db/db mice.
• Administered betaine orally to db/db mice.
• Assessed mRNA expression of lipogenesis-related genes and cellular triglyceride levels.

Main Results:

• Betaine significantly decreased lipid accumulation and suppressed lipogenic gene expression.
• Betaine inhibited the interaction between FoxO6 and PPARγ in liver cells.
• Oral betaine administration ameliorated hepatic steatosis in db/db mice.

Conclusions:

• Betaine ameliorates hepatic steatosis, partly by inhibiting FoxO6/PPARγ interaction.
• This inhibition suppresses lipogenic gene transcription, offering a therapeutic mechanism.
• Betaine demonstrates therapeutic potential for managing fatty liver disease.